Dyne Therapeutics, Inc. (DYN) dividends
DYN on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Dyne Therapeutics, Inc. dividend: key facts
Own Dyne Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next DYN dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Dyne Therapeutics to Participate in Upcoming Investor Conference11 Nov 2026 · GlobeNewsWire
WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive...
- Dyne Therapeutics reports Q3 EPS ($1.06), consensus (88c)5 Nov 2026 · TheFly
Reports Q3 research and development expenses $161.7M vs. $97.2M last year. Reports Q3 general and administrative expenses $35.3M vs. $16.7M last year. Reports cash, cash equivalents and marketable sec...
- Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights5 Nov 2026 · GlobeNewsWire
- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -
- Oppenheimer downgrades Dyne Therapeutics as vHOT uncertainty reduces confidence28 Oct 2026 · TheFly
As previously reported, Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform with a price target of $15, down from $40. Although the firm views Dyneâs DM1 therapy as superiorâ¦
- Dyne Therapeutics downgraded to Perform from Outperform at Oppenheimer28 Oct 2026 · TheFly
Oppenheimer downgraded Dyne Therapeutics (DYN) to Perform from Outperform with a price target of $15, down from $40.
- Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)23 Oct 2026 · GlobeNewsWire
WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
- Piper confident Dyneâs Zeleciment rostudirsen will win January FDA approval3 Oct 2026 · TheFly
Piper Sandler is confident Dyne Therapeuticsâ (DYN) Zeleciment rostudirsen will gain accelerated approval in Duchenne muscular dystrophy boys amenable to exon 51 skipping by the January 21st PDUFA dat...
- Dyne Therapeutics price target lowered to $32 from $50 at H.C. Wainwright3 Oct 2026 · TheFly
H.C. Wainwright lowered the firmâs price target on Dyne Therapeutics (DYN) to $32 from $50 and keeps a Buy rating on the shares. The companyâs update yesterday update supports theâ¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.